Zhejiang Huahai Pharmaceutical Overview

  • Year Founded
  • 1989

Year Founded

  • Status
  • Public

  • Employees
  • 8,797

Employees

  • Stock Symbol
  • 600521

Stock Symbol

  • Investments
  • 11

  • Share Price
  • $2.33
  • (As of Friday Closing)

Zhejiang Huahai Pharmaceutical General Information

Description

Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company's products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Xunqiao
  • Linhai, Zhejiang 317024
  • China
+86 0576
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
SHG
Corporate Office
  • Xunqiao
  • Linhai, Zhejiang 317024
  • China
+86 0576

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zhejiang Huahai Pharmaceutical Stock Performance

As of 20-Nov-2026, Zhejiang Huahai Pharmaceutical’s stock price is $2.33. Its current market cap is $3.5B with 1.5B shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$2.33 $2.47 $2.02 - $2.78 $3.5B 1.5B 26.1M $0.09

Zhejiang Huahai Pharmaceutical Financials Summary

As of 30-Sep-2026, Zhejiang Huahai Pharmaceutical has a trailing 12-month revenue of $1.39B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 4,620,723 4,529,593 4,355,711 3,895,504
Revenue 1,393,277 1,194,099 1,330,566 1,174,397
EBITDA 202,126 231,267 354,955 292,996
Net Income 137,210 37,045 155,946 117,382
Total Assets 3,353,605 3,073,301 2,775,490 2,623,927
Total Debt 1,272,902 1,148,793 1,024,423 988,821
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Zhejiang Huahai Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Zhejiang Huahai Pharmaceutical‘s full profile, request access.

Request a free trial

Zhejiang Huahai Pharmaceutical Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage prep
Pharmaceuticals
Linhai, China
8,797 As of 2025

Suzhou, China
 

Suzhou, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Zhejiang Huahai Pharmaceutical Competitors (3)

One of Zhejiang Huahai Pharmaceutical’s 3 competitors is Alphamab Oncology, a Formerly VC-backed company based in Suzhou, China.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alphamab Oncology Formerly VC-backed Suzhou, China
Innovent Biologics Formerly VC-backed Suzhou, China
BeOne Medicines Formerly PE-Backed Beijing, China
You’re viewing 3 of 3 competitors. Get the full list »

Zhejiang Huahai Pharmaceutical Patents

Zhejiang Huahai Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026228524-A1 Composition of donepezil pamoate and preparation method therefor Pending 27-Apr-2025
WO-2026085702-A1 5-substituted indoline chiral amine, preparation method therefor, and use thereof in preparation of silodosin Pending 22-Oct-2024
WO-2026056878-A1 Preparation method for pyridazinone compound of thyroid hormone analog and intermediate thereof Pending 10-Sep-2024
WO-2026051986-A1 Method for preparing dipeptide compound Pending 05-Sep-2024
WO-2026040943-A1 Method for preparing α-chiral carboxylic acid or α-chiral ester by means of enzyme catalysis Pending 19-Aug-2024
To view Zhejiang Huahai Pharmaceutical’s complete patent history, request access »

Zhejiang Huahai Pharmaceutical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zhejiang Huahai Pharmaceutical Investments (11)

Zhejiang Huahai Pharmaceutical’s most recent deal was a Early Stage VC with Starmab Biologies. The deal was made on 05-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Starmab Biologies 05-Mar-2025 Early Stage VC Drug Discovery
BaiZhen 18-Jul-2024 Early Stage VC Diagnostic Equipment
DDSome Lab 06-Jul-2023 Later Stage VC Drug Delivery
Aurealis Therapeutics 30-Mar-2023 Later Stage VC Drug Discovery
iView Therapeutics 12-Jan-2022 Later Stage VC Drug Discovery
You’re viewing 5 of 11 investments. Get the full list »

Zhejiang Huahai Pharmaceutical ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

38.49 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Zhejiang Huahai Pharmaceutical’s complete esg history, request access »

Zhejiang Huahai Pharmaceutical Exits (3)

Zhejiang Huahai Pharmaceutical’s most recent exit was on 06-Jul-2023 from DDSome Lab. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
DDSome Lab 06-Jul-2023 Completed
  • 2 buyers
GotoBiopharm 14-May-2018 Completed
MicuRx Pharmaceuticals 26-Sep-2016 Later Stage VC Completed
  • 5 buyers
To view Zhejiang Huahai Pharmaceutical’s complete exits history, request access »

Zhejiang Huahai Pharmaceutical FAQs

  • When was Zhejiang Huahai Pharmaceutical founded?

    Zhejiang Huahai Pharmaceutical was founded in 1989.

  • Where is Zhejiang Huahai Pharmaceutical headquartered?

    Zhejiang Huahai Pharmaceutical is headquartered in Linhai, China.

  • What is the size of Zhejiang Huahai Pharmaceutical?

    Zhejiang Huahai Pharmaceutical has 8,797 total employees.

  • What industry is Zhejiang Huahai Pharmaceutical in?

    Zhejiang Huahai Pharmaceutical’s primary industry is Pharmaceuticals.

  • Is Zhejiang Huahai Pharmaceutical a private or public company?

    Zhejiang Huahai Pharmaceutical is a Public company.

  • What is Zhejiang Huahai Pharmaceutical’s stock symbol?

    The ticker symbol for Zhejiang Huahai Pharmaceutical is 600521.

  • What is the current stock price of Zhejiang Huahai Pharmaceutical?

    As of 20-Nov-2026 the stock price of Zhejiang Huahai Pharmaceutical is $2.33.

  • What is the current market cap of Zhejiang Huahai Pharmaceutical?

    The current market capitalization of Zhejiang Huahai Pharmaceutical is $3.5B.

  • What is Zhejiang Huahai Pharmaceutical’s current revenue?

    The trailing twelve month revenue for Zhejiang Huahai Pharmaceutical is $1.39B.

  • Who are Zhejiang Huahai Pharmaceutical’s competitors?

    Alphamab Oncology, Innovent Biologics, and BeOne Medicines are competitors of Zhejiang Huahai Pharmaceutical.

  • What is Zhejiang Huahai Pharmaceutical’s annual earnings per share (EPS)?

    Zhejiang Huahai Pharmaceutical’s EPS for 12 months was $0.09.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process